Company Overview of GlycoMimetics, Inc.
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company develops lead product GMI-1070, a glycomimetic drug candidate that has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. It also develops GMI-1271, a specific E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers; and GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a co...
401 Professional Drive
Gaithersburg, MD 20879
Founded in 2003
Key Executives for GlycoMimetics, Inc.
Total Annual Compensation: $365.7K
Chief Financial Officer
Total Annual Compensation: $216.7K
Chief Medical Officer and Vice President of Clinical Development
Total Annual Compensation: $337.8K
Chief Scientific Officer
Total Annual Compensation: $293.6K
Compensation as of Fiscal Year 2013.
GlycoMimetics, Inc. Key Developments
GlycoMimetics, Inc Announces Delay in the Initiation of the Phase 3 Trial with Rivipansel
Sep 26 14
GlycoMimetics, Inc. announced that it has been informed by Pfizer that initiation of its Phase 3 clinical trial with rivipansel (GMI-1070) will be significantly delayed due to a manufacturing development issue impacting formulated drug supply. Pfizer advised GlycoMimetics that the issue is under review and Pfizer is working diligently to remedy the situation. Pfizer also noted that upon identifying the specific cause and associated remedy of the manufacturing issue, Pfizer will advise GlycoMimetics of a more specific timeframe regarding the commencement of the Phase 3 study.
BioMed Realty Signs New Lease with GlycoMimetics at its Newly Redeveloped Center for Life Science | Shady Grove Campus in Rockville, Maryland
Aug 26 14
BioMed Realty Trust, Inc. announced the signing of a new lease with GlycoMimetics, Inc. for one building comprising approximately 33,800 square feet at the Center for Life Science | Shady Grove in Rockville, Maryland. GlycoMimetics will be moving to the Center for Life Science | Shady Grove, a four building campus with approximately 214,700 square feet or laboratory and office space. The campus is located along the I-270 Corridor in Montgomery County, also known as 'DNA Alley,' which supports several large-scale federal government health agencies, including the Food and Drug Administration, the National Institutes of Health, the Department of Homeland Security and the National Cancer Institute. The area is also home to several world-renowned universities and research institutes, including Johns Hopkins University, the University of Maryland and the Howard Hughes Medical Institute. 77 million dollors.
GlycoMimetics, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 09:00 AM
Aug 15 14
GlycoMimetics, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 09:00 AM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, New York, New York, United States. Speakers: Rachel K. King, Founder, Chief Executive Officer and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|